Low-Dose CT Screening
Low-dose CT screening reduces mortality by 20–24% in high-risk populations. Real-world LDCT screening uptake remains low despite evidence of benefit. Lung cancer is the leading cause of cancer mortality worldwide. System-level, clinician-l…
2 sources - 6 claims
Low-dose CT screening reduces mortality by 20–24% in high-risk populations. Real-world LDCT screening uptake remains low despite evidence of benefit. Lung cancer is the leading cause of cancer mortality worldwide. System-level, clinician-level, and patient-level barriers all impede LDCT uptake. Expanding national screening programmes are increasing demand for flexible diagnostic bronchoscopy, requiring training of more bronchoscopists. CMS coverage of LDCT requires shared decision-making counselling before screening.